United States

Back to map

Showing 101-110 of 325 grants

Title Institution Researcher Program Duration Total Award Amount
Development of β-Cell Targeted Lipid Nanoparticle Therapeutics The University of Chicago Jacob Ryan Enriquez Cures 01-March-2025 to 29-February-2028 $247,790.00
A pilot study assessing the safety of using a monoclonal antibody against CD40 ligand to achieve a calcineurin inhibitor-free immunosuppression regimen in patients with type 1 diabetes mellitus (T1D) and problematic hypoglycemia undergoing islet cell transplantation The University of Chicago Piotr Witkowski Cures 01-February-2024 to 31-January-2026 $250,000.00
A pilot study assessing the safety of using a monoclonal antibody against CD40 ligand to achieve a calcineurin inhibitor-free immunosuppression regimen in patients with type 1 diabetes mellitus (T1D) and problematic hypoglycemia undergoing islet cell transplantation The University of Chicago Piotr Witkowski Cures 01-February-2025 to 31-January-2027 $1,500,000.00
Safety and efficacy assessment of Tegoprubart and calcineurin inhibitors- free immunosuppression therapy for pancreatic islet transplantation in patients with t1DM and chronic kidney disease. The University of Chicago Piotr Witkowski Cures 01-September-2025 to 31-August-2029 $8,500,000.00
Engineered Nanoparticles for Beta Cell-Targeted Therapeutics The University of Chicago Raghavendra Mirmira Cures 01-April-2023 to 31-March-2026 $897,822.00
Project Equity The Sonia Nabeta Foundation Vivian Nabeta Mission 01-May-2024 to 30-April-2026 $245,172.00
Triple therapy for T1DM with insulin, semaglutide and dapagliflozin The Research Foundation of SUNY on behalf of University at Buffalo Paresh Dandona Improving Lives 01-January-2019 to 31-March-2026 $1,808,522.70
Local delivery of immunomodulators to enable systemic immunosuppression-free efficient islet transplantation The Regents of the University of California, San Francisco Bhushan Kharbikar Cures 01-March-2024 to 28-February-2027 $285,000.00
Reducing Diabetes Distress in Adults with Type 1 Diabetes: A pragmatic trial in routine diabetes care. The Regents of the University of California, San Francisco Danielle Hessler Improving Lives 01-August-2023 to 31-July-2026 $1,743,010.00
Sparing ER stressed human beta cells with novel kinase inhibitors of the unfolded protein response (UPR) The Regents of the University of California, San Francisco Feroz Papa Cures 01-August-2023 to 31-July-2026 $960,000.00